

**BULLETIN**

**What Massachusetts COVID-19 Vaccine Providers Need to Know**

**Week of 10/1/21**

**Latest Numbers**

* As of 10/1, **4,624,989** people in Massachusetts have been fully vaccinated.

**Who to Vaccinate this Week**

* **Reminder** Effective 9/24/2021, CDC recommends a Pfizer-BioNTech booster for certain people who received the two-dose Pfizer-BioNTech COVID-19 vaccine at least 6 months ago. *See below for more information.*
* Anyone age 12 and older who lives, works, or studies in Massachusetts is eligible for a vaccine. Health care providers can also vaccinate their patient panels regardless of place of residency.
* Effective 8/13/21, [CDC recommends](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#considerations-additional-vaccine-dose) that people who are moderately to severely immunocompromised receive an additional dose of an mRNA COVID-19 Vaccine (Pfizer-BioNTech or Moderna) at least 28 days after the completion of the initial mRNA COVID-19 vaccine series.

**What to Know this Week**

**Reminder Pfizer-BioNTech boosters**

***These recommendations are ONLY for those who originally received the two-dose series of Pfizer’s COVID vaccine.*** *Booster doses might be recommended in the future for those who received COVID vaccines manufactured by Moderna or Janssen (Johnson & Johnson), but there isn’t enough research available yet to make that call.*

On September 22, 2021, the U.S. Food and Drug Administration (FDA) [amended the emergency use authorization](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine) (EUA) for the Pfizer-BioNTech COVID-19 vaccine to allow for use of a single booster dose, to be administered at least 6 months after completion of the primary series in specific populations. The EUA applies only to the Pfizer-BioNTech COVID-19 vaccine.

On September 23, 2021, CDC’s independent Advisory Committee on Immunization Practices (ACIP) recommended certain populations receive a booster dose of Pfizer-BioNTech’s COVID-19 vaccine at least six months after the completion of their Pfizer-BioNTech primary vaccine series. On September 24, 2021 CDC released interim booster recommendations.

CDC recommends that the following groups **should**receive a booster dose of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after completing their Pfizer-BioNTech primary vaccine series:

* People aged 65 years and older
* Residents aged 18 years and older in long-term care settings
* People aged 50–64 years with [underlying medical conditions](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html)

CDC recommends that a booster dose of Pfizer-BioNTech’s COVID-19 vaccine should be made available so that the following groups **may**receive a booster dose of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after completing their Pfizer-BioNTech primary vaccine series, based on their individual benefits and risks:

* People aged 18–49 years with [underlying medical conditions](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html)
* People aged 18–64 years at increased risk for SARS-CoV-2 exposure and transmission because of occupational or institutional setting

**Reminder** If you are a provider enrolled in the MCVP to administer COVID-19 vaccines, and you administer Pfizer vaccine, you are required to follow CDC/ACIP guidelines and therefore are obligated to offer booster doses.

**Updated** Pfizer resources

* [COVID-19 Vaccine Booster Shot](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html) – updated 9/27/21
* [Clinical Considerations](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html) – updated 9/27/21
* Pfizer [standing orders](https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/standing-orders.pdf) – updated 9/28/21
* CDC [Pfizer webpage](https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html) - watch for updated screening form and other documents.
* Pfizer EUA/Fact Sheet updated September 22
* Providers   <https://www.fda.gov/media/144413/download>
* Recipients  <https://www.fda.gov/media/144414/download>

**New/Updated** Massachusetts resources

* COVID-19 [booster frequently asked questions](https://www.mass.gov/info-details/covid-19-booster-frequently-asked-questions)
* Eligibility [questions and an Eligibility Checker](https://www.mass.gov/info-details/covid-19-booster-frequently-asked-questions#eligibility-) tool
* Search for Vaccine locations: <https://vaxfinder.mass.gov/>
* For individuals who are unable to use Vaxfinder, or have difficulty accessing the internet, the COVID-19 Vaccine Resource Line (Monday through Friday from 8:30 AM to 6:00 PM, Saturday and Sunday 9AM-2PM) by calling 2-1-1 and following the prompts is available for assistance. The COVID-19 Vaccine Resource Line is available in English and Spanish and has translators available to in approximately 100 additional languages.
* COVID-19 [Vaccine Information](https://www.mass.gov/covid-19-vaccine)

**Reminder** CDC guidance supports [coadministration of COVID-19 vaccines with other vaccines](https://urldefense.com/v3/__https%3A/www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html?CDC_AA_refVal=https*3A*2F*2Fwww.cdc.gov*2Fvaccines*2Fcovid-19*2Finfo-by-product*2Fclinical-considerations.html*Coadministration__;JSUlJSUlJSM!!CUhgQOZqV7M!2P7xhpnhvHh6lLG6Y7L6Ns5JobttssHEcT_FMak1AItoC8zI6m6huUfwycVd_j3_ikY$), including influenza vaccines, without regard to timing.

* ACIP 2021/2022 flu recommendations:
	+ Full report: [Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season](https://www.cdc.gov/mmwr/volumes/70/rr/rr7005a1.htm).
	+ Full report pdf: <https://www.cdc.gov/mmwr/volumes/70/rr/pdfs/rr7005a1-H.pdf>
	+ Summary <https://www.cdc.gov/flu/professionals/acip/summary/summary-recommendations.htm>
	+ Summary pdf: <https://www.cdc.gov/flu/pdf/professionals/acip/acip-2020-21-summary-of-recommendations.pdf>

**New COVID Vaccine Ordering** All vaccine orders placed in the MIIS are reviewed and approved within 3 business days after being submitted. Once approved, the Vaccine Management Unit submits orders daily to the CDC for processing and shipping. CDC ships vaccines within 3-4 business days. Orders from sites showing large, expiring, or expired doses of COVID vaccine inventory could be delayed, reduced, or canceled by the Vaccine Management Unit. To prevent orders from being delayed, reduced, or canceled providers must:

* ensure that the MIIS inventory matches the site’s physical inventory
* confirm that all doses administered have been reported and processed in MIIS
* confirm that all storage and handling issues have been reported in MIIS

**Please Note:** Effective immediately, repackaging of COVID vaccines doses for smaller ordering sizes will only be available for primary care provider (PCP) offices – (pediatric, family medicine, internal medicine practices in addition to small specialty practices). Smaller dose orders can still be placed as usual in the MIIS. Individual exceptions to these ordering limitations maybe made on a case by case basis by contacting the Vaccine Unit. **The minimum dose amounts orderable by PCPs are: 60 doses of Pfizer, 50 doses of Moderna, and 25 doses of Johnson & Johnson.** The Vaccine Unit will be fulfilling orders from the State Lab, and courier services will deliver vaccines and ancillary kits. Vaccines are transported in a cooler and in a refrigerated temperature range with a digital data logger. Upon receiving Pfizer and Moderna vaccines, ensure vaccines are placed in the refrigerator and write the beyond used date on the vials. For all other provider sites, the following packaging presentation of COVID-19 vaccines are available for ordering:

* Pfizer 1170 doses
* Moderna 140 doses
* Johnson and Johnson 100 doses

Pfizer 450 dose and Moderna 100 dose packages are no longer available for ordering.

All providers must continue to:

* Administer all doses within 30 days of receipt
* Report to the MIIS all doses within 24 hours of administration
* Agree to [allowable vaccine wastage guidelines](https://www.mass.gov/doc/guidance-on-use-and-allowable-wastage-of-covid-19-vaccine/download)

**Reminder *CDC COVID-19 Vaccination Record Cards:*** As a reminder, COVID-19 Vaccination Record Cards remain property of the U.S. Government until provided to the vaccine recipient following vaccination. Unauthorized use and reproduction of the cards constitute fraud. Healthcare providers are encouraged to keep ample supply of vaccination record cards on site for those patients requesting replacements. Healthcare providers can order extra print copies from the [MA Health Promotion Clearinghouse.](https://massclearinghouse.ehs.state.ma.us/PROG-BID/IM247.html)

**Adherence to MCVP Agreement:** As a reminder, providers are responsible for adhering to all requirements outlined in the MCVP. Specifically, providers must administer COVID-19 vaccines in accordance with all [program requirements and recommendations](https://urldefense.com/v3/__https%3A/www.cdc.gov/vaccines/covid-19/vaccination-provider-support.html__;!!CUhgQOZqV7M!y3QBMl1wDBgmNSyeaTRiKD74ovS_36Lf9kZR5XAzmG_SgHO3oIBIT1Zud2AenSk7Aew$) of CDC, the [Advisory Committee on Immunization Practices](https://urldefense.com/v3/__https%3A/www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html__;!!CUhgQOZqV7M!y3QBMl1wDBgmNSyeaTRiKD74ovS_36Lf9kZR5XAzmG_SgHO3oIBIT1Zud2AeWH5ldwk$), and [FDA](https://urldefense.com/v3/__https%3A/www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines__;!!CUhgQOZqV7M!y3QBMl1wDBgmNSyeaTRiKD74ovS_36Lf9kZR5XAzmG_SgHO3oIBIT1Zud2AeXocNhzI$). This applies to both EUA and FDA approved COVID-19 vaccines. Accordingly, use of these products outside of those that have been approved and authorized by FDA (often referred to as “off-label use”) is not recommended. It would violate the provider agreement and could expose providers to the following risks:

* Administration of the product off label may not be covered under the PREP Act or the PREP Act declaration; therefore, providers may not have immunity from claims.
* Individuals who receive an off-label dose may not be eligible for compensation under the Countermeasures Injury Compensation Program after a possible adverse event.
* CDC has defined the scope of the CDC COVID-19 Vaccination Program in terms of how the USG-provided vaccines may be used in the program. Providers giving off-label doses would be in violation of the CDC Program provider agreement potentially impacting their ability to remain a provider in the CDC program.
* Administration fees may not be reimbursable by payers.

**Resources & Learning Opportunities**

COVID-19 vaccine flyers and EUA factsheets are available in [26 different languages](https://medlineplus.gov/languages/covid19vaccines.html).

CDC’s primary publication for disseminating the science it produces is the *Morbidity and Mortality Weekly Report*, better known as MMWR. The staff at MMWR have launched a new [landing page](https://www.cdc.gov/mmwr/covid19_vaccine_safety.html) to help people find the latest information on COVID-19 vaccine effectiveness and safety.

**New** CDC MMWRs

**September 28, 2021 / Vol. 70 / Early Release**

* [Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12–September 19, 2021](https://www.cdc.gov/mmwr/volumes/70/wr/mm7039e4.htm?s_cid=mm7039e4_w)

**September 24, 2021 / Vol. 70 / Early Release**

* [Association Between K–12 School Mask Policies and School-Associated COVID-19 Outbreaks — Maricopa and Pima Counties, Arizona, July–August 2021](https://www.cdc.gov/mmwr/volumes/70/wr/mm7039e1.htm?s_cid=mm7039e1_w)
* [COVID-19–Related School Closures and Learning Modality Changes — United States, August 1–September 17, 2021](https://www.cdc.gov/mmwr/volumes/70/wr/mm7039e2.htm?s_cid=mm7039e2_w)
* [Pediatric COVID-19 Cases in Counties With and Without School Mask Requirements — United States, July 1–September 4, 2021](https://www.cdc.gov/mmwr/volumes/70/wr/mm7039e3.htm?s_cid=mm7039e3_w)

**Reminder** MDPH Immunization Division is pleased to present [free accredited COVID-19 Vaccine content](https://macovidvax.populationhealthexchange.org/). These training sessions are designed for health care providers, vaccine coordinators, and all health care personnel who handle and/or administer COVID-19 vaccines.

**MDPH Resources**

**Immunization Division Main Number**

For questions about immunization recommendations, disease reporting, etc.

Phone: 617-983-6800 (24/7 MDPH Epi line)

Fax: 617-983-6840

Website: <https://www.mass.gov/topics/immunization>

**MIIS Help Desk**

Phone: 617-983-4335

Fax: 857-323-8321

Email questions to: miishelpdesk@mass.gov

Website: <https://www.mass.gov/service-details/massachusetts-immunization-information-system-miis>

**MDPH Vaccine Unit**

Phone: 617-983-6828

Email questions to: dph-vaccine-management@mass.gov

Website: <https://www.mass.gov/service-details/vaccine-management>

**COVID email box:**

Email questions to: COVID-19-Vaccine-Plan-MA@mass.gov